Evidence map›Paper›PMID 28684848›Full record

ArticleScientific reports2017

Direct protein quantification in complex sample solutions by surface-engineered nanorod probes.

Stefan Schrittwieser, Beatriz Pelaz, Wolfgang J Parak, Sergio Lentijo-Mozo, Katerina Soulantica, Jan Dieckhoff, Frank Ludwig, Joerg Schotter

Abstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Analysing the nanoparticle-protein corona for potential molecular target identification.Journal of controlled release : official journal of the Controlled Release Society · 2020
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Stefan SchrittwieserMolecular Diagnostics, AIT Austrian Institute of Technology, Vienna, Austria. Stefan.Schrittwieser@ait.ac.at.ORCID 0000-0001-5807-3331
Beatriz PelazFachbereich Physik, Philipps-Universität Marburg, Marburg, Germany.
Wolfgang J ParakFachbereich Physik, Philipps-Universität Marburg, Marburg, Germany.ORCID 0000-0003-1672-6650
Sergio Lentijo-MozoLaboratoire de Physique et Chimie des Nano-objets (LPCNO), Université de Toulouse; INSA, UPS, CNRS, Toulouse, France.
Katerina SoulanticaLaboratoire de Physique et Chimie des Nano-objets (LPCNO), Université de Toulouse; INSA, UPS, CNRS, Toulouse, France.ORCID 0000-0003-3033-1620
Jan DieckhoffInstitute of Electrical Measurement and Fundamental Electrical Engineering, TU Braunschweig, Braunschweig, Germany.
Frank LudwigInstitute of Electrical Measurement and Fundamental Electrical Engineering, TU Braunschweig, Braunschweig, Germany.
Joerg SchotterMolecular Diagnostics, AIT Austrian Institute of Technology, Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Detecting biomarkers from complex sample solutions is the key objective of molecular diagnostics. Being able to do so in a simple approach that does not require laborious sample preparation, sophisticated equipment and trained staff is vital for point-of-care applications. Here, we report on the specific detection of the breast cancer biomarker sHER2 directly from serum and saliva samples by a nanorod-based homogeneous biosensing approach, which is easy to operate as it only requires mixing of the samples with the nanorod probes. By careful nanorod surface engineering and homogeneous assay design, we demonstrate that the formation of a protein corona around the nanoparticles does not limit the applicability of our detection method, but on the contrary enables us to conduct in-situ reference measurements, thus further strengthening the point-of-care applicability of our method. Making use of sandwich assays on top of the nanorods, we obtain a limit of detection of 110 pM and 470 pM in 10-fold diluted spiked saliva and serum samples, respectively. In conclusion, our results open up numerous applications in direct protein biomarker quantification, specifically in point-of-care settings where resources are limited and ease-of-use is of essence.

Indexed as

Biosensing TechniquesAntibodiesBiomarkers, TumorEquipment DesignErb-b2 Receptor Tyrosine KinasesHumansImmunoassayLimit of DetectionNanoparticlesNanotubesPoint-of-Care SystemsProtein CoronaReference StandardsSalivaAntibodiesBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesProtein Corona

Identifiers

PMID28684848
PMCPMC5500566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.